Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Allgenesis Biotherapeutics Inc. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action represents the active prosecution focus for the company at the USPTO. The focus on Biotechnology & Pharmaceuticals indicates that the company is pursuing protection for medical or biological innovations. Practitioners should be aware of the technical complexity inherent in this technology area.
The pending office action is assigned to 1 distinct examiner and a distinct art unit. The alignment of the action with a distinct examiner and 1 distinct art unit suggests a highly centralized examination process. There is no fragmentation of the portfolio across different departments, which can often lead to more consistent prosecution outcomes. This structure allows for a focused strategy within the specific art unit involved.
CRAIGO, WILLIAM A is the busiest examiner, handling the busiest examiner pending action. Since there is only a distinct examiner for the entire portfolio, CRAIGO, WILLIAM A is the sole point of contact for the company's current USPTO matters. This centralization allows for a direct interaction model. Practitioners can dedicate their efforts to the specific requirements of CRAIGO, WILLIAM A to resolve the pending office action.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CRAIGO, WILLIAM A | 1 | 49.2% | +38.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18798718 | OPHTHALMIC FORMULATIONS OF TYROSINE KINASE INHIBITORS, METHODS OF USE THEREOF, AND PREPARATION METHODS THEREOF | CRAIGO, WILLIAM A | 5d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18798718 | OPHTHALMIC FORMULATIONS OF TYROSINE KINASE INHIBITORS, METHODS OF USE THEREOF, AND PREPARATION METHODS THEREOF | CRAIGO, WILLIAM A | 5d overdue |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18798718 | OPHTHALMIC FORMULATIONS OF TYROSINE KINASE INHIBITORS, METHODS OF USE THEREOF, AND PREPARATION METHODS THEREOF | CRAIGO, WILLIAM A | 1615 | §102§103Other | Final Rejection | 5d overdue | Pending | Aug 08, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial